Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade

HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells

(2018) Chunyu Cao et al.   INTERNATIONAL JOURNAL OF CANCER

Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine

(2018) Barbara Pasculli et al.   SEMINARS IN CANCER BIOLOGY

The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer

(2017) Kai Wang et al.   HUMAN PATHOLOGY

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

(2017) Mizuki Nishino et al.   Nature Reviews Clinical Oncology

Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)

(2016) J. M. Kim et al.   ANNALS OF ONCOLOGY

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

(2016) Hong Zheng et al.   CLINICAL CANCER RESEARCH

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression

(2016) C Cao et al.   ONCOGENE

Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer

(2016) Gulidanna Shayan et al.   OncoImmunology

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

(2016) Marcel A. Deken et al.   OncoImmunology

Dysregulation of the Epigenome in Human Breast Cancer

(2015) Rupninder Sandhu et al.   AMERICAN JOURNAL OF PATHOLOGY

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes

(2015) H. R. Ali et al.   ANNALS OF ONCOLOGY

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epigenetic reprogramming in breast cancer: From new targets to new therapies

(2014) Tiffany A. Katz et al.   ANNALS OF MEDICINE

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients

(2014) H. R. Ali et al.   ANNALS OF ONCOLOGY

Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity

(2014) Jason W. Griffith et al.   Annual Review of Immunology

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity

(2014) Suzanne Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

(2014) H. Wimberly et al.   Cancer Immunology Research

Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells

(2013) Shauna N. Vasilatos et al.   CARCINOGENESIS

Lung tumor NF-κB signaling promotes T cell–mediated immune surveillance

(2013) Emily L. Hopewell et al.   JOURNAL OF CLINICAL INVESTIGATION

NF- B Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells

(2012) R. Muthuswamy et al.   CANCER RESEARCH

The H3K4me3 Histone Demethylase Fbxl10 Is a Regulator of Chemokine Expression, Cellular Morphology, and the Metabolome of Fibroblasts

(2012) Andreas Janzer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells

(2011) Yi Huang et al.   BREAST CANCER RESEARCH AND TREATMENT

Binding of the JmjC Demethylase JARID1B to LSD1/NuRD Suppresses Angiogenesis and Metastasis in Breast Cancer Cells by Repressing Chemokine CCL14

(2011) Q. Li et al.   CANCER RESEARCH

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology

(2009) Soyoung Lim et al.   CARCINOGENESIS

Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes

(2009) Y. Huang et al.   CLINICAL CANCER RESEARCH

Polyamine analogues targeting epigenetic gene regulation

(2009) Yi Huang et al.   Essays in Biochemistry

LSD1: oxidative chemistry for multifaceted functions in chromatin regulation

(2008) Federico Forneris et al.   TRENDS IN BIOCHEMICAL SCIENCES